Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-Assisted Psychotherapy for PTSD in Military Veterans
NCT07792538Phase 2Not yet recruiting
- Sponsor
- ARQ National Psychotrauma Centre
- Start
- Dec 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of psilocybin in post-traumatic stress disorder (PTSD), sponsored by ARQ National Psychotrauma Centre. Primary endpoints: Clinician-Administered PTSD Scale for DSM-5 Revised, Semi-structured interview and 8 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT07792538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07792538.